Keywords: integrilin, combination, boosts, artery, patency, final, data
Integrilin combination boosts artery patency
Article | 15 November 2000
The final data from Schering-Plough and COR Therapeutics' INTRO-AMIstudy, evaluating the antiplatelet drug Integrilin (eptifibatide) with half-dose alteplase (Genentech's Activase), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
